(OMER) Announces Plan to File Infringement Suit Against ANDA Filer

SEATTLE, Aug. 17, 2015  — Omeros Corporation (NASDAQ: OMER) today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC (Par) in response to the Abbreviated New Drug Application (ANDA) filed by Par seeking FDA approval to market a generic version of Omeros’ commercial drug Omidria^® (phenylephrine and ketorolac injection) 1%/0.3%. Omidria is approved by the U.S. Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. As reported in the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2015, Omeros received a notice from Par on July 27, 2015, which addresses the ANDA and Par’s request to market a generic version of Omidria pursuant to Paragraph IV of the Hatch-Waxman Act following expiration of the drug’s New Product Exclusivity and, if applicable, the subsequent Pediatric Exclusivity, but prior to the expiration of three patents published in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, which have terms extending to as late as 2033. Approximately 3.8 million cataract and lens replacement procedures are projected in the U.S. in 2015.

Omeros currently owns 34 issued patents worldwide related to Omidria. The patents that are listed in the Orange Book were granted by multiple examiners in multiple art groups based on review of prior art from multiple searches. Omeros is highly confident in its patent estate protecting Omidria.

Omeros has reviewed Par’s Paragraph IV assertions and plans to file a patent infringement suit against Par within 45 days of Omeros’ receipt of Par’s notice. In this regard, Omeros has engaged a prominent Hatch-Waxman litigation team at Covington & Burling LLP. Filing of the planned lawsuit will trigger what is generally a 30-month stay of FDA action on Par’s ANDA. Issued U.S. patents are presumed to be valid, and only clear and convincing evidence presented in federal court can establish invalidity.  Independent of its patents, Omidria has also received 36-month market exclusivity through the New Product Exclusivity provided by the Federal Food, Drug, and Cosmetic Act as well as an additional six months of market exclusivity available upon successful completion of the company’s pediatric clinical plan according to the Written Request from FDA.

“Generic manufacturers challenging branded drug products is ‘business as usual’ in the pharmaceutical industry and, based on its track record this is not an uncommon activity for Par,” stated Gregory A. Demopulos M.D., chairman and chief executive officer of Omeros. “This action confirms our belief in the market potential of Omidria. We are confident in the strength of our product’s broad patent estate. We have engaged one of the premier biotech patent litigation teams in the country to pursue aggressively our case against Par, so I do not anticipate this effort becoming a distraction for Omeros. We remain focused on continuing to build on our successful launch of Omidria and on increasing the product’s market uptake.”

About Omidria^®
Omeros’ PharmacoSurgery^® product Omidria^® contains the mydriatic (pupil-dilating) agent phenylephrine and the anti-inflammatory agent ketorolac and was developed for use during cataract or other IOL replacement surgery. The FDA has approved Omidria for use during cataract surgery or IOL replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain.

Important Risk Information for Omidria^®
Systemic exposure of phenylephrine may cause elevations in blood pressure. In clinical trials, the most common reported ocular adverse reactions at two to 24 percent are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation; incidence of adverse events was similar between placebo-treated and Omidria-treated patients. Omidria^® must be added to irrigation solution prior to intraocular use. Omidria is not approved for use in children.

About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery^® platform, the company’s first drug product, Omidria^® (phenylephrine and ketorolac injection) 1%/0.3%, has been approved by the FDA for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. In the European Union, European Commission has approved Omidria for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. Omeros has partnered its arthroscopic product, OMS103, for commercialization with Fagron Sterile Services and affiliated JCB Laboratories. Omeros has five clinical-stage development programs focused on: complement-related thrombotic microangiopathies; Huntington’s disease, schizophrenia, and cognitive impairment; and addictive and compulsive disorders. In addition, Omeros has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, product commercialization including with respect to Omidria^® and OMS103, risks associated with Omeros’ ability to partner and commercialize Omidria in Europe, Omeros’ unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2015. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

(GBT) Closing of IPO, Exercise of Over-Allotment Option

(CFRXW) (CFRX) FDA Grants Fast Track Designation to ContraFect’s CF-301

(ESPR) Update on the ETC-1002 Development Program

Company on Track to Initiate Phase 3 Development Program in 2015 Conference Call and Webcast on Monday, August 17, 2015 at 4:30 p.m. Eastern Time

(AVEO) Exclusive Worldwide License Agreement for AV-380

AVEO Oncology (NASDAQ:AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody (the “Product”).

Under the terms of the agreement, AVEO will receive an upfront payment of $15 million and will be eligible to receive reimbursement, clinical, sales and regulatory-based milestone payments totaling $311 million assuming successful advancement of the Product. AVEO will also be eligible to receive tiered royalties on product sales ranging from high single digits to a low double-digit. Novartis will be responsible for all clinical development, manufacturing and commercialization activities and costs associated with the Product.

“AV-380 holds great promise as a potential treatment for cachexia secondary to multiple disease states, including cancer, chronic kidney disease, congestive heart failure and chronic obstructive pulmonary disease,” said Michael Bailey, AVEO’s president and chief executive officer. “Novartis brings resources and expertise to bear on advancing this program, which we believe provides the optimal path forward toward realizing its full potential.”

About Cachexia and GDF15

Cachexia is a complex metabolic syndrome associated with malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions. Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases. It affects some five million individuals in the United States¹.

GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro-inflammatory state may be responsible for many of the symptoms associated with cachexia. Preclinical data show that inhibition of GDF15 results in a switch from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia.

About AVEO

AVEO Oncology (AVEO) is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide improvements in patient outcomes where significant unmet medical needs exist. AVEO’s proprietary Human Response Platform™ has delivered unique insights into cancer and related disease biology that AVEO is seeking to leverage in the clinical development strategy of its therapeutic candidates. For more information, please visit the company’s website at www.aveooncology.com.

AVEO Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of AVEO within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. The words “anticipate,” “expect,” “intend,” “may,” “plan,” “could,” “should,” “seek,” or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about the expected benefits of AVEO’s agreement with Novartis, the amount, timing and potential receipt of payments under the Novartis agreement and AVEO’s clinical development plans for tivozanib in renal cell and colorectal cancer. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that AVEO makes due to a number of important factors, including risks relating to: AVEO’s ability to maintain its agreement with Novartis; AVEO’s ability, and the ability of any licensees, to demonstrate to the satisfaction of applicable regulatory agencies the safety, efficacy and clinically meaningful benefit of AVEO’s product candidates; AVEO’s ability to successfully implement its strategic plans; AVEO’s ability to successfully enroll and complete clinical trials of its product candidates; AVEO’s ability to achieve and maintain compliance with all regulatory requirements applicable to its product candidates; AVEO’s ability to obtain and maintain adequate protection for intellectual property rights relating to its product candidates and technologies; developments and expenses related to AVEO’s ongoing shareholder litigation and SEC inquiry; AVEO’s ability to raise the substantial additional funds required to achieve its goals; unplanned capital requirements; adverse general economic and industry conditions; competitive factors; and those risks discussed in the section titled “Risk Factors” in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.

References

¹ Morley et al. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735–43.

(VPCO) Reports Second Quarter 2015 Results

Sales increased 105%; Gross Margins and Adjusted EBITDA Improved Compared to First Quarter of 2015

DANIA BEACH, Fla., Aug. 17, 2015  — Vapor Corp. (NASDAQ CM: VPCO, VPCOU) (“Vapor” or the “Company”), a leading U.S.-based distributor and retailer of vaporizers, e-liquids and e-cigarettes, today announced its financial and operating results for the second quarter ended June 30, 2015.

Second Quarter 2015 Financial Highlights

• Net Sales More Than Double Q2 2015 vs Q1 2015
  Net sales for the second quarter of 2015 were $3.0 million compared to $1.5 million in the first quarter of 2015, an increase of 105%. This increase was primarily due to the Company’s retail Vape Stores expansion strategy and increased wholesale sales.
• Gross Margins Increase
  Gross margins for the second quarter of 2015 increased to 45.2% from 25.3% the same quarter one year ago and from (-12.4)% from the first quarter of 2015. This increase was primarily related to product returns and discounts that were recognized in the previous quarters, as well as improved operating margins from the Company’s retail operations. The Company has struck new wholesale agreements with many of its retail customers to minimize the impact of future product returns and discount programs.
• Adjusted EBITDA Loss Reduced 46% in Q2 2015 vs Q1 2015
  Adjusted EBITDA, a non-GAAP financial measure, was ($1.5) million in the second quarter of 2015 compared to ($2.8) million in the first quarter of 2015. This significant reduction was a result of the Company’s two-pronged strategy to shift its wholesale business to concentrate on smaller retail chains (generally 150 stores and less), while seeing the benefit from operating more of its vape stores for a full quarter.

“In the second quarter of 2015, we drove sequential quarterly revenue growth of 105% through our revised wholesale strategy and the strong performance of our ‘The Vape Store’ retail locations,” said Jeff Holman, CEO of Vapor Corp. “The recent completion of our $41.4 million capital raise offers us the ability to significantly expand our direct-to-consumer model, ‘The Vape Store,’ by opening new locations and acquiring existing vaporizer retailers, which will be transitioned over to our brand. We currently have 11 ‘The Vape Store’ locations, with a goal of increasing the number of company-owned retail stores by 20 to 30 locations before the end of the calendar year.”

Greg Brauser, President of Vapor Corp., stated, “Vapor Corp.’s competitive differentiator is rooted in our buying power and fast-growing network of retail locations. As we continue to acquire stores and expand our brand, our economies of scale and purchasing power will increasingly improve, further enhancing our ability to offer the industry’s highest quality e-liquids and vaporizers to customers at reduced prices. These strengths elevate our competitiveness in the approximately $3.5 billion vaporizer market and favorably position us to achieve our long-term goal of being the leading national vaporizer retailer.”

Recent Business Highlights

• Completed an offering of 3,761,657 convertible preferred stock units at $11 per unit for gross proceeds of approximately $41.4 million and net proceeds to Vapor Corp. of approximately $38.7 million.
• Opened 11th “The Vape Store” location in Kissimmee, FL, in response to the growing consumer demand for vaping products and in recognition of the shift in consumer preferences to shop in vape-dedicated stores.
• Fully implemented a new point-of-sale and retail software system in all of the Company’s Vape Stores to improve efficiencies and controls as part of its expansion plan.
• Completed overhaul and relaunch of TheVapeStoreOnline.com, Vapor Corp.’s e-commerce channel and premier destination for e-liquids, devices, tanks and coils, as well as educational resources for both new and experienced vaping customers.
• Successfully relaunched Vapor Corp.’s affiliate program, whereby affiliates are supplied with a unique coupon code and receive commission for every product purchased online at Vapor Corp.’s e-commerce websites when a customer enters their code at checkout.
• Rolled out a rewards program across all retail store locations and on Vapor Corp.’s e-commerce site.
• Launched “Naked Fish”, a new, premium line of dripper e-liquids. The Naked Fish line is mixed using the highest quality USP Kosher Food Grade Vegetable Glycerin and Propylene Glycol.

“On the heels of our recent capital raise, we are in a much stronger financial position.  We are debt-free as of today and have what is likely the largest cash war chest in this segment of the industry. During the second quarter we completed the recognition of all returns and write-downs on expired e-cigarette product. In addition, we have entered new agreements with many of our larger wholesale retail customers that minimize our responsibility for the sell-through of product through their stores, mitigating our exposure to the magnitude of returns that stymied the e-cig industry in 2014,” concluded Mr. Holman.

Non-GAAP Financial Measure

This press release includes both financial measures in accordance with Generally Accepted Accounting Principles, or GAAP, as well as a non-GAAP financial measure. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flows that either excludes or includes amounts that are not normally included or excluded in the most directly comparable measure calculated and presented in accordance with GAAP. Non-GAAP financial measures should be viewed as supplemental to, and should not be considered as alternatives to net income, operating income, and cash flow from operating activities, liquidity or any other financial measures. They may not be indicative of the historical operating results of Vapor nor are they intended to be predictive of potential future results. Investors should not consider non-GAAP financial measures in isolation or as substitutes for performance measures calculated in accordance with GAAP.

Our management uses and relies on adjusted earnings before interest, tax, depreciation and amortization, plus non-cash stock based compensation and changes in the fair value of derivatives or Adjusted EBITDA, as a non-GAAP financial measure. We believe that both management and shareholders benefit from referring to the following non-GAAP financial measure in planning, forecasting and analyzing future periods. Our management uses this non-GAAP financial measure in evaluating its financial and operational decision making and as a means to evaluate period-to-period comparison.  Our management recognizes that the non-GAAP financial measure has inherent limitations because of the excluded items described below.

We have included a reconciliation of our non-GAAP financial measure to the most comparable financial measures calculated in accordance with GAAP. We believe that providing the non-GAAP financial measure, together with the reconciliation to GAAP, helps investors make comparisons between Vapor and other companies. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measure and the corresponding GAAP measure provided by each company under applicable SEC rules.

The following table presents a reconciliation of Adjusted EBITDA to Net loss, a GAAP financial measure:

About Vapor Corp.
Vapor Corp., a NASDAQ company, is a U.S. based distributor and retailer of vaporizers, e-liquids and electronic cigarettes. It recently acquired the retail store chain “The Vape Store” as part of a merger with Vaporin, Inc. The Company’s innovative technology enables users to inhale nicotine vapor without smoke, tar, ash or carbon monoxide. Vapor Corp. has a streamlined supply chain, marketing strategies and wide distribution capabilities to deliver its products. The Company’s brands include VaporX®, Krave®, Hookah Stix® and Vaporin™ and are distributed to retail stores throughout the U.S. and Canada. The Company sells direct to consumer via e-commerce and Company-owned brick-and-mortar retail locations operating under “The Vape Store” brand.

Safe Harbor Statement
This press release includes forward-looking statements including statements regarding future profitability, opening up to 20-30 new vape stores and minimizing future product returns. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. The results anticipated by any or all of these forward-looking statements might not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include a shift in consumer preferences, contractual difficulties which adversely affect Vapor’s acquisition strategy and future federal and/or state regulation regarding vaporizers and tobacco alternatives. Further information on our risk factors is contained in our filings with the SEC, including the Prospectus dated July 23, 2015. We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.

(RCII) “Make a Difference Scholarship” Offers Aid amidst Skyrocketing College Costs

Rent-A-Center, Inc. (NASDAQ/NGS:RCII) today announced 60 U.S. high school and undergraduate students will share $60,000 in Rent-A-Center scholarships for distinguishing themselves academically and through civic engagement.

Having distributed $610,000 in scholarships since its establishment in 2004, Rent-A-Center’s Make A Difference scholarship provides 60 $1,000 awards annually to Rent-A-Center customers, their children, and the children of Rent-A-Center employees.

The scholarships come on the heels of a recent Gallup poll that found that college-funding worries are a top money concern for U.S. parents.

“Rent-A-Center has a long tradition of supporting education,” said Kenneth Jones, Rent-A-Center’s public affairs manager. “It’s gratifying to give back to the communities we serve and help offset tuition costs.”

Among other requirements, scholarship applicants must be pursuing their first undergraduate degree at an accredited two- or four-year college, university, vocational school or technical school in the United States or Puerto Rico.

A diverse group of students from across 12 states, this year’s awardees have a variety of academic focuses including engineering, business and psychology.

More information, including program guidelines and applications, can be found at https://www.scholarshipamerica.org/makeadifference/.

About Rent-A-Center:

A rent-to-own industry leader, Rent-A-Center is headquartered in Plano, Texas and operates more than 3,000 stores in the United States, Puerto Rico, Canada, and Mexico. The Company employs over 20,000 coworkers. Learn more at www.rentacenter.com.

Rent-A-Center
Kenneth Jones, 972-801-1815
media@rentacenter.com

(TTWO) Announces WWE® 2K16 Soundtrack Fit to #RaiseSomeHell

2K today announced the in-game soundtrack details for WWE® 2K16, the forthcoming release in the flagship WWE video game franchise. The soundtrack will feature 11 unique tracks from established and emerging artists that transcend multiple genres, including alternative, hip-hop, classic rock, heavy metal, country and electronic dance. The full WWE 2K16 soundtrack was revealed exclusively during Release on Beats 1 on Apple Music and is available now for streaming at http://apple.co/1DSFmcf. WWE 2K16 is currently scheduled for release on October 27, 2015 in North America and October 30, 2015 internationally for Xbox One and Xbox 360, as well as the PlayStation®4 and PlayStation®3 computer entertainment systems.

The WWE 2K16 soundtrack is scheduled to include the following artists and songs:

• Billy Idol – “Rebel Yell”
• Diplo (feat. Faustix & Imanos and Kai) – “Revolution”
• Fashawn (feat. Nas & Aloe Blacc) – “Something To Believe In”
• Kid Ink – “Hello World”
• Marilyn Manson – “Deep Six”
• MGK (feat. Victoria Monet) – “A Little More”
• Run-DMC – “It’s Tricky”
• Skid Row – “Youth Gone Wild”
• Twenty One Pilots – “Heavydirtysoul”
• Yelawolf – “Till It’s Gone” [Dan Heath Remix]
• Zac Brown Band (feat. Chris Cornell) – “Heavy Is The Hand”
• Zedd (feat. Logic and X-Ambassadors) – “Transmission”

“Building on the success of the in-game soundtrack curated by WWE Superstar John Cena® last year, we were enthusiastic about partnering with 2K to raise the bar higher for WWE 2K16 with a memorable list of world-renowned artists,” said Neil Lawi, Senior Vice President, WWE Music Group. “The WWE 2K16 soundtrack offers a diverse and exciting group of artists and songs including iconic tracks ‘Rebel Yell’ and ‘Youth Gone Wild,’ two of today’s most sought-after electronic dance masterminds Diplo and Zedd, and current ‘it’ artists Twenty One Pilots and Yelawolf.”

“Music plays a vital role in the WWE Universe, from WWE Superstar and Diva ring entrances to official pay-per-view themes, and inherently evokes WWE memories and emotions in all of us,” said Chris Snyder, Vice President of Marketing at 2K. “The WWE 2K16 soundtrack delivers a premium entertainment experience and is certain to raise some hell through its notable worldwide names and multiple music genres.”

Developed collaboratively by Yuke’s and Visual Concepts, a 2K studio, WWE 2K16 is not yet rated by the ESRB. WWE 2K16 is currently scheduled for release on Xbox One, Xbox 360, PS4™ and PS3™ on October 27, 2015 in North America and October 30, 2015 internationally. Consumers who pre-order WWE 2K16 at any participating retailer will receive two playable characters – each depicting global action film icon Arnold Schwarzenegger from The Terminator and Terminator 2: Judgment Day films – at no extra cost on launch day.

For more information on WWE 2K16 and 2K, visit wwe.2k.com, become a fan on Facebook, follow the game on Twitter and Instagram using the hashtags #WWE2K16 and #RaiseSomeHell or subscribe on YouTube.

2K is a wholly owned publishing label of Take-Two Interactive Software, Inc. (NASDAQ:TTWO).

T1, THE TERMINATOR, T2, TERMINATOR 2: JUDGMENT DAY, ENDOSKELETON, and any depiction of Endoskeleton are trademarks of Studiocanal S.A. All Rights Reserved. ©2015 Studiocanal S.A.®

About WWE

WWE, a publicly traded company (NYSE:WWE), is an integrated media organization and recognized leader in global entertainment. The company consists of a portfolio of businesses that create and deliver original content 52 weeks a year to a global audience. WWE is committed to family friendly entertainment on its television programming, pay-per-view, digital media and publishing platforms. WWE programming reaches more than 650 million homes worldwide in 35 languages. WWE Network, the first-ever 24/7 over-the-top premium network that includes all 12 live pay-per-views, scheduled programming and a massive video-on-demand library, is currently available in more than 170 countries. The company is headquartered in Stamford, Conn., with offices in New York, Los Angeles, London, Mexico City, Mumbai, Shanghai, Singapore, Dubai, Munich and Tokyo.

Additional information on WWE (NYSE:WWE) can be found at wwe.com and corporate.wwe.com. For information on our global activities, go to http://www.wwe.com/worldwide/.

Trademarks: All WWE programming, talent names, images, likenesses, slogans, wrestling moves, trademarks, logos and copyrights are the exclusive property of WWE and its subsidiaries. All other trademarks, logos and copyrights are the property of their respective owners.

Forward-Looking Statements: This press release contains forward-looking statements pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995, which are subject to various risks and uncertainties. These risks and uncertainties include, without limitation, risks relating to: WWE Network; major distribution agreements; our need to continue to develop creative and entertaining programs and events; a decline in the popularity of our brand of sports entertainment; the continued importance of key performers and the services of Vincent K. McMahon; possible adverse changes in the regulatory atmosphere and related private sector initiatives; the highly competitive, rapidly changing and increasingly fragmented nature of the markets in which we operate and greater financial resources or marketplace presence of many of our competitors; uncertainties associated with international markets; our difficulty or inability to promote and conduct our live events and/or other businesses if we do not comply with applicable regulations; our dependence on our intellectual property rights, our need to protect those rights, and the risks of our infringement of others’ intellectual property rights; the complexity of our rights agreements across distribution mechanisms and geographical areas; potential substantial liability in the event of accidents or injuries occurring during our physically demanding events including, without limitation, claims relating to CTE; large public events as well as travel to and from such events; our feature film business; our expansion into new or complementary businesses and/or strategic investments; our computer systems and online operations; a possible decline in general economic conditions and disruption in financial markets; our accounts receivable; our revolving credit facility; litigation; our potential failure to meet market expectations for our financial performance, which could adversely affect our stock; Vincent K. McMahon exercising control over our affairs, and his interests may conflict with the holders of our Class A common stock; a substantial number of shares which are eligible for sale by the McMahons and the sale, or the perception of possible sales, of those shares could lower our stock price; and the relatively small public “float” of our Class A common stock. In addition, our dividend is dependent on a number of factors, including, among other things, our liquidity and cash flow, strategic plan (including alternative uses of capital), our financial results and condition, contractual and legal restrictions on the payment of dividends (including under our revolving credit facility), general economic and competitive conditions and such other factors as our Board of Directors may consider relevant. Forward-looking statements made by the Company speak only as of the date made, are subject to change without any obligation on the part of the Company to update or revise them, and undue reliance should not be placed on these statements.

About Take-Two Interactive Software

Headquartered in New York City, Take-Two Interactive Software, Inc. is a leading developer, publisher and marketer of interactive entertainment for consumers around the globe. The Company develops and publishes products through its two wholly-owned labels Rockstar Games and 2K. Our products are designed for console systems and personal computers, including smartphones and tablets, and are delivered through physical retail, digital download, online platforms and cloud streaming services. The Company’s common stock is publicly traded on NASDAQ under the symbol TTWO. For more corporate and product information please visit our website at http://www.take2games.com.

About 2K

Founded in 2005, 2K develops and publishes interactive entertainment globally for console systems, handheld gaming systems and personal computers, including smartphones and tablets, which are delivered through physical retail, digital download, online platforms and cloud streaming services. 2K publishes titles in today’s most popular gaming genres, including shooters, action, role-playing, strategy, sports, casual, and family entertainment. The 2K label has some of the most talented development studios in the world today, including Firaxis Games, Visual Concepts, Hangar 13, Cat Daddy Games and 2K China. 2K’s stable of high quality titles includes the critically acclaimed BioShock®, Borderlands™, and XCOM® franchises, the beloved Sid Meier’s Civilization series, the innovative Evolve™, the popular WWE 2K franchise and NBA 2K, the #1 rated and #1 selling basketball franchise*. 2K is headquartered in Novato, California and is a wholly owned label of Take-Two Interactive Software, Inc. (NASDAQ:TTWO). For more information, please visit www.2k.com.

*According to 2008 – 2015 Metacritic.com and The NPD Group estimates of U.S. retail video game sales through July 2015.

“PlayStation” and “PS3” are registered trademarks. “PS4” is a trademark of Sony Computer Entertainment Inc.

All trademarks and copyrights contained herein are the property of their respective holders.

Cautionary Note Regarding Forward-Looking Statements

The statements contained herein which are not historical facts are considered forward-looking statements under federal securities laws and may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “will,” or words of similar meaning and include, but are not limited to, statements regarding the outlook for the Company’s future business and financial performance. Such forward-looking statements are based on the current beliefs of our management as well as assumptions made by and information currently available to them, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may vary materially from these forward-looking statements based on a variety of risks and uncertainties including: our dependence on key management and product development personnel, our dependence on our Grand Theft Auto products and our ability to develop other hit titles, the timely release and significant market acceptance of our games, the ability to maintain acceptable pricing levels on our games, our ability to raise capital if needed and risks associated with international operations. Other important factors and information are contained in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2015, including the risks summarized in the section entitled “Risk Factors,” the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2015, and the Company’s other periodic filings with the SEC, which can be accessed at www.take2games.com. All forward-looking statements are qualified by these cautionary statements and apply only as of the date they are made. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

(ODP) Helps Children and Families Affected by Memorial Day Floods

When 11 inches of rain drenched the Greater Houston area over Memorial Day weekend, more than 12,000 homes and businesses were damaged – and countless children and families were affected.

To help some of these children start the new school year on the right foot, the Office Depot Foundation donated 2,000 colorful new sackpacks containing essential school supplies to the Greater Houston Storm Recovery Network – a collaboration of nonprofit, faith-based, local, state and national organizations that are working together to share information and resources to assist with recovery and rebuilding. The Foundation – the independent charitable giving arm of Office Depot^® (NASDAQ:ODP) – announced the donations during a special Back-to-School Celebration at a Houston Office Depot store.

The Greater Houston Storm Recovery Network will distribute the sackpacks to children living in neighborhoods that were affected by the flooding. “These new sackpacks and the supplies they contain will be a valuable resource for children and families who are still feeling the impact of the floods,” said Lynae Novominsky, Vice-Chair of the Network and Volunteer Services Coordinator for Jewish Family Service of Houston. “Based upon past experience, recovery of many of these residents is expected to take from nine to 18 months, if not more.”

The Office Depot Foundation is making the donations during the 15^th year of its award-winning National Backpack Program. By the end of this year, Office Depot and the Office Depot Foundation will have given away more than 3.7 million backpacks and sackpacks since the National Backpack Program began in 2001. In total, the Foundation donated 5,000 sackpacks to Houston-area schools, nonprofit organizations and government agencies this week.

“We believe that every child should have the opportunity to go to school with dignity and hope,” said Office Depot Foundation President Mary Wong. “These sackpacks and school supplies help to level the playing field.

“At the same time, this donation supports the Office Depot Foundation’s commitment to helping communities recover and rebuild after natural disasters,” Wong continued. “We are proud to support the work of the Greater Houston Storm Recovery Network as it continues to help residents of this community get back on their feet.”

The Office Depot Foundation also is supporting recovery and rebuilding efforts in Houston through its sponsorship of the National Disaster Help Desk for Business, a 24-hour toll-free hotline managed by the U.S. Chamber of Commerce Foundation’s Center for Corporate Citizenship. Businesses and nonprofit organizations can access resources and expert guidance by calling 1-888-MY-BIZ-HELP or (888) 692-4943.

The collaboration between the Office Depot Foundation and the Greater Houston Storm Recovery Network was suggested by Feed the Children, an Oklahoma City-based nonprofit organization that worked with numerous agencies in the Houston area to provide relief following the floods. “At Feed the Children we believe in championing partnerships,” said Travis Arnold, Interim President and CEO. “We know that when we unite together with other nonprofits we will have a greater impact. That is why we were excited to connect the Office Depot Foundation with the Greater Houston Storm Recovery Network and help serve these families that were impacted by the flooding.”

More information about the National Backpack Program can be found on the Office Depot Foundation’s Facebook page at www.facebook.com/officedepotfoundation. To learn more about the Office Depot Foundation and its initiatives, go to www.officedepotfoundation.org/.

About the Office Depot Foundation

The Office Depot Foundation is an independent foundation − tax exempt under IRC Sec. 501(c)(3) − that serves as the independent charitable giving arm of Office Depot, Inc. In keeping with its mission, Listen Learn Care^®, the Foundation supports a variety of programs that give children tools to succeed in school and in life; build the capacity of nonprofit organizations through collaboration and innovation; and help communities prepare for disasters, as well as recovering and rebuilding afterwards. For more information, visit www.officedepotfoundation.org.

About the Greater Houston Storm Recovery Network

The Greater Houston Storm Recovery Network (the “Network”) is a collaborative of local 501(c)(3) agencies formed as a Long-Term Recovery Committee in response to the Memorial Day flooding in the Greater Houston area. The Network is pleased that it is able to start its distribution of early donations to help children start the school year off with supplies and uniforms and will be providing more resources to those families in need via its case management agencies. For more information about how to receive services, volunteer or donate, visit www.houstonfloodrecovery.org.

About Feed the Children

Feed the Children believes that it can create a world where no child goes to bed hungry. Since 1979, Feed the Children has grown into one of the largest U.S.-based charities. It is accredited by GuideStar Exchange and the BBB Wise Giving Alliance, maintain a 3-star rating from Charity Navigator, and is also a member of InterAction. Through its network agencies, Feed the Children distributed over $344 million in food, other necessities, educational supplies and medicine, impacting close to nine million individuals in the U.S. and over 4.9 million individuals globally, in fiscal year 2014.

IMAGES AVAILABLE ON REQUEST

Office Depot Foundation
Leon Rubin, 561-251-8075 (mobile)
lrubin@jkggroup.com

(BKEPP) to Present at EnerCom, As Well As Citi Conferences

Blueknight Energy Partners, L.P. (“BKEP” or the “Partnership”) (NASDAQ: BKEP) (NASDAQ:BKEPP), a midstream energy company providing integrated services for companies engaged in the production, distribution and marketing of crude oil, asphalt and other petroleum products, announced today that Mark Hurley, Chief Executive Officer; Brian Melton, Vice-President of Business Development; and Alex Stallings, Chief Financial Officer, will present at EnerCom’s Oil and Gas Conference in Denver, Colorado at 8:25 a.m. Mountain Daylight Time, on Tuesday, August 18, 2015.

A live audio webcast of the presentation along with materials used during the conference will be accessible in the Investors section of BKEP’s website at www.bkep.com or by accessing http://www.theoilandgasconference.com on Tuesday, August 18th.

After the EnerCom Conference, Blueknight officers will conduct individual meetings with members of the investment community at the Citi MLP/Midstream Infrastructure Conference in Las Vegas, Nevada on Wednesday, August 19 and Thursday, August 20, 2015. The presentation materials used during the conference will be accessible in the Investors section of BKEP’s website at www.bkep.com on Wednesday, August 19th.

About Blueknight Energy Partners, L.P.

BKEP owns and operates a diversified portfolio of complementary midstream energy assets consisting of approximately 7.7 million barrels of crude oil storage located in Oklahoma and Texas, approximately 6.6 million barrels of which are located at the Cushing Oklahoma Interchange, approximately 900 miles of crude oil pipeline located primarily in Oklahoma and Texas, approximately 250 crude oil transportation and oilfield services vehicles deployed in Kansas, Colorado, New Mexico, Oklahoma and Texas and approximately 7.3 million barrels of combined asphalt product and residual fuel oil storage located at 43 terminals in 22 states. BKEP provides integrated services for companies engaged in the production, distribution and marketing of crude oil, asphalt and other petroleum products. BKEP is headquartered in Oklahoma City, Oklahoma. For more information, visit the Partnership’s web site at www.bkep.com.

(SOCB) To Be Acquired By (BNCN)

HIGH POINT, N.C., Aug. 14, 2015  — BNC Bancorp (“BNC,” NASDAQ: BNCN), the holding company for Bank of North Carolina, and Southcoast Financial Corporation (“Southcoast,” NASDAQ: SOCB), the holding company for Southcoast Community Bank, have entered into a definitive agreement pursuant to which BNC will acquire all of the common stock of Southcoast in a stock transaction valued at approximately $95.5 million, based on the closing price of BNC common stock on August 13, 2015.

Southcoast, headquartered in Mt. Pleasant, South Carolina, operates 10 branches in Mt. Pleasant, Charleston, Moncks Corner, Johns Island, Summerville, Goose Creek and North Charleston, South Carolina. As of June 30, 2015, Southcoast reported approximately $506 million in assets, $383 million in loans, and $361 million in deposits. Upon completion of the transaction, BNC is expected to have approximately $6.0 billion in assets, $4.5 billion in loans, and $4.9 billion in deposits. The transaction is expected to be immediately accretive to BNC’s fully diluted earnings per share and tangible book value per share, excluding deal costs.

Under the terms of the agreement, which has been approved by the Boards of Directors of both companies, Southcoast shareholders will receive a fixed price of $13.35 for each share of Southcoast common stock, payable in shares of BNC common stock based upon the 20-day volume weighted average price of BNC common stock prior to the closing of the merger (the
“VWAP”), subject to minimum and maximum exchange ratios. If the VWAP immediately prior to the merger is equal to or less than $19.00, then each share of Southcoast common stock will be converted into 0.7026 of a share of BNC common stock. If the VWAP immediately prior to the merger is equal to or more than $22.00, then each share of Southcoast common stock will be converted into 0.6068 of a share of BNC common stock. The transaction, which is subject to regulatory approval, the approval of the shareholders of Southcoast, and other customary conditions, is expected to close in the first quarter of 2016.

Commenting on the announcement, Rick Callicutt, President and Chief Executive Officer of BNC, said, “We are pleased to announce the combination of BNC and Southcoast. This partnership will allow us to expand our presence in one of the fastest growing and most dynamic regions in the Southeast, the Charleston and Mt. Pleasant, South Carolina markets. We are most excited about Wayne Pearson and his team joining BNC. Our combined companies will be well positioned for further growth in the Charleston and Mt. Pleasant markets with approximately $800 million in assets and a top-five deposit market share in the Charleston-North Charleston, SC MSA. The similar culture and core values of Southcoast and BNC will allow us to accelerate the integration, deepen existing customer relationships, and focus on expansion in these highly-sought after markets. The Southcoast team has built a bank that aligns with our vision of a high performing community bank that creates value for all of its stakeholders while ‘Delivering More’ than our customers expect.”

Callicutt continued, “The addition of Southcoast’s 10 offices, along with our upcoming acquisition of seven branches of CertusBank, N.A. in the Upstate Region, will allow BNC to grow our South Carolina franchise by approximately 17 office locations in the two fastest growing areas in the state.”

Wayne Pearson, Chairman and Chief Executive Officer of Southcoast, added, “We are pleased to join forces with BNC to provide enhanced and long-term value to our customers and communities. Our combination with BNC, with combined total assets of approximately $6.0 billion, will provide greater capital resources and operational scale that will allow us to grow with the robust Charleston and Mt. Pleasant economies and capture additional market share. In addition, BNC’s track record for creating and growing shareholder value will be a major plus for the Southcoast shareholder base.”

Troutman Sanders LLP provided legal counsel to BNC, while FIG Partners, LLC served as financial advisor to BNC and Sandler O’Neill + Partners LP served as a special advisor to BNC. Haynsworth Sinkler Boyd, P.A. provided legal counsel to Southcoast, while Banks Street Partners, LLC served as financial advisor to Southcoast.

INVESTOR PRESENTATION

Further information on the terms of this transaction will be included in a Form 8-K to be filed by BNC with the Securities and Exchange Commission (the “SEC”).

ABOUT BNC BANCORP

Headquartered in High Point, North Carolina, BNC Bancorp is the parent company of Bank of North Carolina, a commercial bank with total assets in excess of $5.0 billion. Bank of North Carolina provides a complete line of banking and financial services to individuals and businesses through its 57 banking offices in Virginia, North and South Carolina. The Bank currently has 12 locations in South Carolina and nine locations in Virginia that operate as BNC Bank. Bank of North Carolina is insured by the FDIC and is an equal housing lender. BNC Bancorp’s stock is traded and quoted in the NASDAQ Capital Market under the symbol “BNCN.” BNC Bancorp’s website is www.bncbancorp.com.

FORWARD-LOOKING STATEMENTS

This Current Report contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. In general, forward-looking statements usually use words such as “may,” “believe,” “expect,” “anticipate,” “intend,” “will,” “should,” “plan,” “estimate,” “predict,” “continue” and “potential” or the negative of these terms or other comparable terminology, including statements related to the expected timing of the closing of the merger, the expected returns and other benefits of the merger, to shareholders, expected improvement in operating efficiency resulting from the merger, estimated expense reductions resulting from the transactions and the timing of achievement of such reductions, the impact on and timing of the recovery of the impact on tangible book value, and the effect of the merger on BNC’s capital ratios. Forward-looking statements represent management’s beliefs, based upon information available at the time the statements are made, with regard to the matters addressed; they are not guarantees of future performance. Forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time and could cause actual results or financial condition to differ materially from those expressed in or implied by such statements.

Factors that could cause or contribute to such differences include, but are not limited to, the possibility that expected benefits may not materialize in the time frames expected or at all, or may be more costly to achieve; that the merger may not be timely completed, if at all; that prior to completion of the merger or thereafter, the parties’ respective businesses may not perform as expected due to transaction-related uncertainties or other factors; that the parties are unable to implement successful integration strategies; that the required regulatory, shareholder, or other closing conditions are not satisfied in a timely manner, or at all; reputational risks and the reaction of the parties’ customers to the merger; diversion of management time to merger-related issues; and other factors and risk influences contained in the cautionary language included under the headings “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in BNC’s Form 10-K for the year ended December 31, 2014 and other documents subsequently filed by BNC with the SEC. Consequently, no forward-looking statement can be guaranteed. Neither BNC nor Southcoast undertakes any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For any forward-looking statements made in this Current Report on Form 8-K, the exhibits hereto or any related documents, BNC and Southcoast claim protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

ADDITIONAL INFORMATION

This communication is being made in respect of the Merger involving BNC and Southcoast. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the merger, BNC will file with the SEC a registration statement on Form S-4 that will include a proxy statement/prospectus for the shareholders of Southcoast. BNC also plans to file other documents with the SEC regarding the merger with Southcoast. Southcoast will mail the final proxy statement/prospectus to its shareholders. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS REGARDING THE MERGER AND ANY OTHER RELEVANT DOCUMENTS CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE MERGER. The proxy statement/prospectus, as well as other filings containing information about BNC and Southcoast, will be available without charge, at the SEC’s website (http://www.sec.gov). Copies of the proxy statement/prospectus and other documents filed with the SEC in connection with the merger can also be obtained, when available, without charge, from BNC’s website (http://www.bncbancorp.com) and Southcoast’s website (http://www.southcoastbank.com).

Participants in the Merger Solicitation.

BNC and Southcoast, and certain of their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the shareholders of Southcoast in respect of the merger. Information regarding the directors and executive officers of BNC and Southcoast and other persons who may be deemed participants in the solicitation of the shareholders of Southcoast in connection with the merger will be included in the proxy statement/prospectus for Southcoast’s special meeting of shareholders, which will be filed by BNC with the SEC. Information about BNC’s directors and executive officers can also be found in BNC’s definitive proxy statement in connection with its 2015 annual meeting of shareholders, as filed with the SEC on April 14, 2015, and other documents subsequently filed by BNC with the SEC. Information about Southcoast’s directors and executive officers can also be found in Southcoast’s Annual Report on Form 10-K, as filed with the SEC on March 12, 2015, and other documents subsequently filed by Southcoast with the SEC. Additional information regarding the interests of such participants will be included in the proxy statement/prospectus and other relevant documents regarding the merger filed with the SEC when they become available.

(PBMD) Announces Commencement of Milestones for IMP701 Program

(GALT) Receives U.S. Patent Notice of Allowance

Broad Coverage Includes Use of Various Pectin Compounds for Chronic Kidney Disease Associated with the Development of Fibrosis, Established Kidney Fibrosis, Chronic Lung Disease Associated with the Development of Fibrosis and Established Lung Fibrosis

NORCROSS, Ga., Aug. 13, 2015  — Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for patent application number 13/726,900, titled “Galactose-pronged polysaccharides in a formulation for antifibrotic therapies.” When issued, the patent will extend coverage of the Company’s pectin-derived compounds (including broad molecular weight ranges and other sources of pectin) to include treatment of chronic kidney disease associated with the development of fibrosis, established kidney fibrosis, chronic lung disease associated with the development of fibrosis and established lung fibrosis.

The Company’s lead compound, GR-MD-02, is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that is comprised predominantly of galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. GR-MD-02 is currently in a Phase 2 program in subjects with non-alcoholic steatohepatitis (NASH) with cirrhosis and NASH with advanced fibrosis.

“We are very pleased to bolster our portfolio of intellectual property with this patent and its broad coverage of pectin sources and molecular weight,” said Peter G. Traber, M.D., chief executive officer, president and chief medical officer of Galectin Therapeutics. “When issued, this patent will add to the Company’s current method of use patents for liver fibrosis, NASH, NASH with fibrosis, NASH cirrhosis and diabetic kidney disease to permit additional fibrotic disease method claims,” he added.

Claims in this new patent include administering pectin-derived compound parenterally to a patient having at least one of the four aforementioned diseases where the established fibrosis or progression of the fibrosis or cirrhosis is inhibited or slowed down. Additional specific claims encompass deriving the compound from citrus pectin, apple pectin, soybean hull pectin or sugar beet pectin with a molecular weight between 2 kDa and 400kDa. Also covered is the step of administering the modified galacto-rhamnogalacturonan compound in an admixture with a therapeutic agent, where the agent is an antifibrotic compound.

About Galectin Therapeutics

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding patents that are expected to allow the potential expansion of Galectin’s development program for GR-MD-02 to include treatment of chronic kidney disease associated with the development of fibrosis, established kidney fibrosis, chronic lung disease associated with the development of fibrosis and established lung fibrosis. Claims in issued patents may not afford meaningful protection for our technological products. In addition, patents issued may be challenged and subsequently narrowed, invalidated or circumvented.   Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of GR-MD-02 or any of its other drugs in development. The Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies. Carbohydrates are a relatively new drug class, and regulatory requirements are evolving; and we cannot assure that will be able to meet such requirements in a timely and cost effective manner in the manufacturing and characterization of our products. Regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.

CONTACT: Jack Callicutt, Chief Financial Officer
         (678) 620-3186
         ir@galectintherapeutics.com

         LHA
         Kim Golodetz
         (212) 838-3777
         kgolodetz@lhai.com

(ONTX) Announces Submission of IND Application for Pivotal Phase 3 Trial for IV Rigosertib

Key Milestone in Positioning Rigosertib on Approval Track for HR-MDS

Pivotal Phase 3 Trial Expected to Begin in Second Half of 2015

NEWTOWN, Pa., Aug. 13, 2015  — Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for IV rigosertib as a treatment for higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agent (HMA) therapy.  Upon clearance, the IND enables Onconova to initiate a randomized, controlled pivotal Phase 3 trial in patients with HR-MDS that have failed prior HMA therapy.

“We are pleased to achieve this important milestone, which positions rigosertib back on an approval track in HR-MDS,” said Ramesh Kumar, Ph.D., President and CEO of Onconova.  “We plan to submit Clinical Trial Applications (CTAs) in several European countries shortly.  Onconova anticipates initiating enrollment in the new Phase 3 study in the second half of 2015.”

The pivotal trial, designated 04-30 or “INSPIRE”, will enroll HR-MDS patients under 80 years of age who had progressed on, or failed to respond to, previous treatment with HMAs within the first nine months of initiation of HMA treatment, and had their last dose of HMA therapy within six months prior to enrollment in the trial.  The primary endpoint of this study will be overall survival, and an interim analysis is anticipated.  This randomized trial of approximately 225 patients will be conducted at about 100 sites globally.  Enrollment in this trial is expected to begin later this year, though the ability to conduct the trial as planned will require additional financing.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova’s clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company’s most advanced product candidate, two other candidates are clinical stage, and several candidates are in pre-clinical stages.  For more information, please visit http://www.onconova.com.

About Rigosertib

Rigosertib is a small molecule that inhibits cellular signaling by acting as a Ras mimetic. This is believed to be mediated by direct binding of rigosertib to the Ras-binding domain (RBD) found in many Ras effector proteins, including the Raf kinases and PI3K. The initial therapeutic focus for rigosertib is myelodysplastic syndromes (MDS), a group of bone marrow disorders characterized by ineffective formation of blood cells that often converts into acute myeloid leukemia (AML). Clinical trials with intravenous (IV) and oral formulations of rigosertib are being conducted at leading institutions in the U.S. and Europe.

Forward Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events or Onconova Therapeutics, Inc.’s future operations, clinical development of Onconova’s product candidates and presentation of data with respect thereto, regulatory approvals, expectations regarding the sufficiency of Onconova’s cash and other resources to fund operating expenses and capital expenditures, Onconova’s anticipated milestones and future expectations and plans and prospects. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including our need for additional financing and current plans and future needs to scale back operations if adequate financing is not obtained, the success and timing of our clinical trials and regulatory approval of protocols, and those discussed under the heading “Risk Factors” in our most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q.

Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACT: Onconova Therapeutics

                 Benjamin Hoffman, 267-759-3036

                 bhoffman@onconova.us

(REXI) Authorizes Additional Share Repurchases

(OHGI) Aishuo App Wins Exclusive VoIP-Supply Contract for KeyIdea

Aishuo App Surpasses 7 Million Downloads; Approaches Halfway Milestone for 2 Year, 15 Million Subscriber Goal

(KMPH) to Report Pharmacokinetic Data From Intranasal Human Abuse Study

Conference Call and Live Audio Webcast Today at 4:30 p.m. ET

CORALVILLE, Iowa, Aug. 13, 2015  — KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the Company will report the results from its intranasal human abuse liability study of KP201/APAP on today’s scheduled 4:30 p.m. ET call to review KemPharm’s corporate and financial results for the second quarter ended June 30, 2015.

The single-center, cross-over design pharmacokinetic study (KP201.A03) primarily measured the amount of hydrocodone released from KP201 (without acetaminophen) compared directly to hydrocodone bitartrate when both substances were insufflated (i.e. snorted).

Conference Call Information:

Interested participants and investors may access the conference call by dialing either:

• (866) 395-2480 (U.S.)
• (678) 509-7538 (international)

An audio webcast will be accessible via the Investor Relations section of the KemPharm website http://investors.kempharm.com/. A replay of the call will be available for 90 days beginning at approximately 5:30 p.m., ET today.

About KemPharm:

KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of prodrugs to treat serious medical conditions through its LAT platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders. For more information on KemPharm, please visit www.kempharm.com.

Caution Concerning Forward Looking Statements:

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21 E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: KemPharm’s financial resources and whether they will be sufficient to meet KemPharm’s business objectives and operational requirements; results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by KemPharm’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. KemPharm’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning KemPharm’s business are described in additional detail in KemPharm’s Registration Statement on Form S-1 (Registration No. 333-202660) declared effective April 15, 2015, and KemPharm’s other Periodic and Current Reports filed with the Securities and Exchange Commission. KemPharm is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: For KemPharm, Inc.:	
         Gordon K. "Rusty" Johnson
         319-665-2575
         info@kempharm.com

         Media / Investor Contacts:
         Jason Rando / Joshua Drumm, Ph.D.
         Tiberend Strategic Advisors, Inc.
         212-375-2665 / 2664
         jrando@tiberend.com
         jdrumm@tiberend.com

(SWSH) Announces Agreement to Sell Its U.S. Operations to (ECL) Ecolab

Transaction Expected to Close During the Fourth Quarter Pending Approval of the Company’s Stockholders

CHARLOTTE, N.C., Aug. 13, 2015  — Swisher Hygiene Inc. (“Swisher”) (NASDAQ:SWSH), a leading service provider of essential hygiene and sanitizing solutions, today announced that the Company agreed to sell the stock of its wholly owned U.S. subsidiary Swisher International, Inc. and other assets relating to Swisher’s U.S. operations, which comprise all of Swisher’s remaining operating interests, to Ecolab Inc. for $40.0 million in cash, of which $2.0 million is subject to a holdback for working capital adjustments. In the transaction, Swisher will retain certain debt and liabilities as set forth in the Purchase Agreement governing the sale. Completion of the transaction is subject to stockholder approval and other customary conditions.

“We believe the transaction is in the best interest of our stockholders and creates a very positive opportunity for our customers and employees. This transaction provides a broader customer base of business, additional service support, and the resources to expand our business and better service our customers. We believe Swisher International’s business model complements Ecolab’s existing institutional U.S. operations and will benefit our customers and employees,” said William M. Pierce, President and Chief Executive Officer of Swisher.

Conference Call

Swisher will host a conference call and live webcast to discuss this announcement as well as its second quarter 2015 results today at 8:30 a.m. Eastern Time.

The conference call can be accessed over the phone by dialing (855) 437-4412 or for international callers by dialing (484) 756-4295 and providing conference ID 5067258; please dial-in 10 minutes before the start of the call. A replay will be available two hours after the call and can be accessed by dialing 1-855-859-2056 or for international callers by dialing 1-404-537-3406; the conference ID is 5067258. The replay will be available until Wednesday, August 19, 2015.

Cautionary Statement on Forward-Looking Information

All statements other than statements of historical fact contained in this press release constitute “forward-looking information” or “forward-looking statements” within the meaning of the U.S. federal securities laws and the Securities Act (Ontario) and are based on the expectations, estimates and projections of management as of the date of this press release unless otherwise stated. All statements other than historical facts are, or may be, deemed to be forward looking statements. The words “plans,” “expects,” “is expected,” “scheduled,” “estimates,” or “believes,” or similar words or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” “might,” or “will be taken,” “occur,” and similar expressions identify forward-looking statements.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Swisher as of the date of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. All of these assumptions have been derived from information currently available to Swisher including information obtained by Swisher from third-party sources. These assumptions may prove to be incorrect in whole or in part. All of the forward-looking statements made in this press release are qualified by the above cautionary statements and those made in the “Risk Factors” section of Swisher’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission, available on www.sec.gov, and with Canadian securities regulators available on Swisher’s SEDAR profile at www.sedar.com, and Swisher’s other filings with the Securities and Exchange Commission and with Canadian securities regulators available on Swisher’s SEDAR profile at www.sedar.com. The forward-looking information set forth in this press release is subject to various assumptions, risks, uncertainties and other factors that are difficult to predict and which could cause actual results to differ materially from those expressed or implied in the forward-looking information. Swisher disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

About Swisher Hygiene Inc.

Swisher Hygiene Inc. is a NASDAQ listed service company delivering essential hygiene and sanitizing solutions to customers in a wide range of end-markets, with a particular emphasis on the foodservice, hospitality, retail and healthcare industries. These solutions are typically delivered by employees on a regularly scheduled basis and involve providing Swisher’s customers with consumable products such as detergents, cleaning chemicals, soap and hand sanitizers, paper and specialty products. Most of these offerings are coupled with the rental and servicing of dish machines, dispensing equipment and additional services such as the cleaning of restrooms and other facilities. EPA-registered disinfectants that meet the Centers for Disease Control and Prevention’s guidelines are also offered to assist customers with their need to disinfect environmental surfaces that may harbor specific viruses. Swisher is committed to service excellence, as what Swisher does matters to thousands of customers on a daily basis, helping to create the cleanest and healthiest environments.

Additional Information and Where to Find It

In connection with the proposed sale by Swisher Hygiene Inc. of its wholly owned subsidiary Swisher International, Inc. and other assets relating to Swisher Hygiene’s U.S. operations to Ecolab, Inc. (the “Sale Transaction”), Swisher Hygiene will file a proxy statement with the Securities and Exchange Commission (“SEC”). Swisher Hygiene will mail the definitive proxy statement to its stockholders.  INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION ABOUT SWISHER HYGIENE AND THE SALE TRANSACTION.  Investors and security holders may obtain a free copy of the definitive proxy statement, when it becomes available, and other documents filed by Swisher Hygiene with the SEC at the SEC’s web site at www.sec.gov.

The definitive proxy statement and such other documents also will be available for free on Swisher Hygiene’s website at www.swsh.com under the Investors page or by directing a written request to Swisher Hygiene Inc., 4725 Piedmont Row Drive, Suite 400, Charlotte, North Carolina 28210 Attention: Investor Relations.

Participants in a Solicitation

Swisher Hygiene and its directors, executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies from its stockholders in connection with the Sale Transaction. Information concerning the interests of Swisher Hygiene’s participants in the solicitation is set forth in Swisher Hygiene’s Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on April 1, 2015 and Amendment No. 1 to the Annual Report on Form 10-K/A for the year ended December 31, 2014, which was filed with the SEC on April 30, 2015, and in the definitive proxy statement relating to the Sale Transaction when it becomes available.

CONTACT: For Further Information, Please Contact:

         Swisher Hygiene Inc.

         Investor Contact:
         Amy Simpson
         Phone: (704) 602-7116

(EXFO) Multi-Million Dollar Order for Automatic Fiber Network Monitoring Solution

EXFO’s solution was selected based on next-generation OTDR technology and innovative software that bring the highest level of automation to monitor nearly 3,000 km of mission-critical fiber plant

QUEBEC CITY, Aug. 12, 2015 – EXFO Inc. (NASDAQ: EXFO; TSX: EXF) announced today it has obtained a multi-million dollar order from a government entity in the Asia-Pacific region for a fiber monitoring system that will monitor a mission-critical, high-speed, IP/MPLS (Internet Protocol/Multiprotocol Label Switching) network spanning over nearly 3,000 kilometers.

EXFO’s fiber monitoring solution, branded as NQMSfiber, provides real-time surveillance of an optical network 24 hours per day, seven days per week. It is indispensable for detecting fiber bends, fiber cuts and fiber degradations over time, all of which can impede communications across a network.

NQMSfiber consists of optical time domain reflectometers (OTDRs), in the form of remote test units, providing high resolution and accurate loss measurements along fiber links. These units are combined with a web-based element management system (EMS), offering users a centralized access to results and an intuitive interface to analyze alarms and other events. This order is expected to be recognized into revenue in fiscal 2016.

“EXFO’s next-generation OTDR technology and innovative software, offering the highest level of automation and integration, played a major role in securing this deal, since they ensure unmatched network operation and maintenance,” said Stephane Chabot, Vice-President of EXFO’s Physical-Layer Division. “The added capabilities of our fiber monitoring system, with sophisticated functions like self-learning, programmable alarm management and dashboard reporting on fiber availability, placed our solution head-and-shoulders above the competition. In short, our fiber monitoring solution not only provides our customers with valuable, end-to-end visibility and key performance indicators (KPIs), but it also saves them precious time and money.”

About EXFO
EXFO enables extraordinary experiences on global networks. Our test, service assurance and network visibility solutions allow equipment manufacturers and network operators to deliver a wealth of services to consumers, while increasing network capacity and reducing operating costs. From a company executive holding a telepresence meeting with overseas staff to a runner transferring data from wearable technology, EXFO’s inherent expertise and powerful analytics render these events commonplace. Simply put, we have evolved over our 30-year history to ensure unmatched quality of service and quality of experience on next-generation fixed and mobile networks. EXFO has a staff of approximately 1600 people in 25 countries, supporting more than 2000 customers worldwide. For more information, visit www.EXFO.com and follow us on the EXFO Blog, Twitter, LinkedIn, Facebook, Google+ and YouTube.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and we intend that such forward-looking statements be subject to the safe harbors created thereby. Forward-looking statements are statements other than historical information or statements of current condition. Words such as may, expect, believe, plan, anticipate, intend, could, estimate, continue, or similar expressions or the negative of such expressions are intended to identify forward-looking statements. In addition, any statement that refers to expectations, projections or other characterizations of future events and circumstances are considered forward-looking statements. They are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those in forward-looking statements due to various factors including, but not limited to, macroeconomic uncertainty as well as capital spending and network deployment levels in the telecommunications industry (including our ability to quickly adapt cost structures with anticipated levels of business and our ability to manage inventory levels with market demand); future economic, competitive, financial and market conditions; consolidation in the global telecommunications test and service assurance industry and increased competition among vendors; capacity to adapt our future product offering to future technological changes; limited visibility with regards to timing and nature of customer orders; longer sales cycles for complex systems involving customers’ acceptances delaying revenue recognition; fluctuating exchange rates; concentration of sales; timely release and market acceptance of our new products and other upcoming products; our ability to successfully expand international operations; our ability to successfully integrate businesses that we acquire; and the retention of key technical and management personnel. Assumptions relating to the foregoing involve judgments and risks, all of which are difficult or impossible to predict and many of which are beyond our control. Other risk factors that may affect our future performance and operations are detailed in our Annual Report, on Form 20-F, and our other filings with the U.S. Securities and Exchange Commission and the Canadian securities commissions. We believe that the expectations reflected in the forward-looking statements are reasonable based on information currently available to us, but we cannot assure that the expectations will prove to have been correct. Accordingly, you should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this document. Unless required by law or applicable regulations, we undertake no obligation to revise or update any of them to reflect events or circumstances that occur after the date of this document.

(IDN) Launches Law ID with Enhanced Functionality

Intellicheck Mobilisa, Inc. (NYSE MKT: IDN), the industry leader in identity authentication, verification and validation solutions, today announced the launch of Law ID^®,the industry’s most accurate and customizable solution for immediately authenticating the identification and determining the status of an unknown and potentially dangerous contact.^. The product is ideal for assisting in traffic stops, detective and undercover operations, security at outdoor events and everywhere law enforcement is on duty and immediately needs to know a contacts threat status. Law ID can be used on mobile devices at the point of contact to instantaneously access Department of Motor Vehicles, State and Federal law enforcement data sources to deliver real-time status on the contact.

Intellicheck currently has pilot agreements with police departments in three different states to install, evaluate and potentially purchase Law ID. These law enforcement agencies include departments in a major metropolitan area, a suburban unit adjacent to one of the nation’s largest cities and a sprawling, largely rural community department. Once the pilots are completed and the departments adopt Law ID, these three clients cumulatively represent annual recurring revenue potential in excess of $500K, with a total addressable market that is estimated to exceed $300M dollars annually. Having agreements with each of these distinctive size-class organizations demonstrates the scalability and effectiveness of Intellicheck’s Law ID solution for all types of law enforcement departments and agencies serving the public in a wide variety of operational environments and missions. Law ID also achieved another major milestone by passing a federal Criminal Justice Information System (CJIS) evaluation, allowing the system to access secure national law enforcement data sources.

Law ID reads embedded information on driver licenses and other government issued identification documents, while concurrently searching Department of Motor Vehicles, State, Federal and other authoritative law enforcement data sources. The real-time search results can deliver critical information, to the law enforcement officer’s smartphone including outstanding warrants, wants, and BOLOS (Be On the Look-Outs) along with photos, vehicle and weapon registration information, identification validation and additional important information. New functionality enhancements enable real-time querying and display of results from local law enforcement databases as well as providing interoperability and instantaneous access to critical information. Additionally, an upgraded interface to police records management systems (RMS) provides greater speed and accuracy in completing officer reporting forms. Better reporting accuracy coupled with less time writing reports and searching for information optimizes both the use of law enforcement officers’ time and police department resources.

Law ID offers several major safety, cost and timesaving benefits. It is an affordable SaaS solution that is scalable from small to large police departments, as well as state and federal law enforcement and criminal justice agencies. Law ID can make an important safety difference during officer-citizen encounters by quickly de-escalating potentially tense interactions. During field contacts, law enforcement officials using Law ID on a mobile device can scan a driver license for identity authentication and other law enforcement information while maintaining visibility with the contact. This eliminates the officer’s need to return to the patrol car to enter contact data or to initiate radio inquiries. Law ID can instantaneously return vital data to the palm of the officer’s hand. The Law ID solution parses the query returns and the interface highlights critical information so an officer instantly knows if there is reason for heightened awareness. By also providing an individual’s photo from a returned query, Law ID provides law enforcement officers with the visual ability to help verify a positive match on the contact. In addition, Law ID reduces third party dispatch costs and minimizes radio traffic, keeping critical communications paths open for emergency use while preventing information from being monitored using police scanners. Law ID also eliminates bulky, additional equipment with its smartphone and tablet-based capabilities.

Intellicheck CEO Dr. William Roof commented, “Law ID increases officer and citizen safety. It can help quickly de-escalate a potentially tense situation by providing rapid data access and a quick and intuitive summary of critical law enforcement information. For every police department, state and federal law enforcement and other criminal justice agencies, our feature-enhanced solution is robust, scalable and affordable. We are excited to begin deploying units to our first three representative departments and expect to have positive results.”

Intellicheck Mobilisa’s robust patent portfolio of 20 patents includes many pertaining to identification technology. Intellicheck’s identity authentication solutions support customers in the national defense, law enforcement, retail, hospitality and financial markets. The Company’s products scan, authenticate and analyze components of identity documents including driver licenses, military identification cards and other government forms of identification containing magnetic stripe, barcode and smart chip information. Once extracted from the identity card, the information can be used to provide safety, security and efficiencies throughout these markets.

About Intellicheck Mobilisa

Intellicheck Mobilisa is an industry leader in identity authentication, verification and validation systems. The Company holds over 20 patents including many pertaining to identification technology. Its identity solutions support customers in the law enforcement, national defense, hospitality, retail and financial markets. The Company’s products scan, authenticate and analyze components of identity documents including driver licenses, military identification cards and other government forms of identification containing magnetic stripe, barcode and smart chip information. For more information on Intellicheck Mobilisa and ICMOBIL, please visit www.icmobile.com.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward looking statements including, without limitation, the statements regarding Intellicheck Mobilisa’s proposed offering, that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to general market conditions, development and product commercialization activities, and the success of its research, development and expansion of sales and marketing team, plans and strategies. These and other risks and uncertainties are identified and described in more detail in Intellicheck Mobilisa’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2014, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Intellicheck Mobilisa undertakes no obligation to publicly update or revise any forward-looking statements.

(IMDZ) Announces Phase 2 Cancer Immunotherapy Trial Collaboration

Plan to Evaluate Combination of CMB305 and Genentech’s Atezolizumab in Patients With Soft Tissue Sarcoma

SEATTLE and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2015  — Immune Design (Nasdaq:IMDZ) today announced it has entered into a clinical trial collaboration with Genentech, a member of the Roche Group, to evaluate the safety and efficacy of Immune Design’s CMB305 cancer immunotherapy product candidate combined with the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) in a randomized Phase 2 trial in patients with soft tissue sarcoma.

CMB305 is a “prime-boost” cancer immunotherapy product designed to synergistically induce anti-tumor cytotoxic T lymphocytes (CTLs) to target NY-ESO-1, a tumor antigen found in a broad set of tumors. Atezolizumab is a PD-L1 antagonist and is designed to block inhibitory T-cell checkpoints and allow cytotoxic T cells to reach the tumor. The randomized, open label Phase 2 trial will evaluate CMB305 and atezolizumab in patients with locally advanced, relapsed, or metastatic synovial sarcoma or myxoid/round-cell liposarcoma, two types of sarcoma that tend to express NY-ESO-1 broadly.

“The combination of CMB305, which is designed to generate and expand tumor-specific CD8 T cells, with atezolizumab, which is designed to remove the tumor-induced blockade, makes profound sense from a mechanistic perspective,” said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer of Immune Design. “We are pleased to begin this collaboration with Genentech and explore the potential synergy of these product candidates, which will hopefully bring significant benefit to patients.”

About CMB305

CMB305 is a cancer immunotherapy product candidate combining two potentially synergistic agents, LV305 and G305. LV305 is a hybrid vector from the ZVex^TM discovery platform that specifically targets dendritic cells (DCs) in vivo and delivers the RNA for NY-ESO-1, enabling the DCs to express the entire tumor antigen and potentially induce a diverse set of CTLs targeting NY-ESO-1. G305, in contrast, is designed to boost the CTL response via the induction of antigen-specific CD4 “helper” T cells. G305 consists of recombinant NY-ESO-1 protein formulated with a proprietary synthetic small molecule called glucopyranosyl lipid A (GLA), the novel TLR4 agonist at the core of the GLAAS platform. CMB305 is intended to be an “off-the shelf” therapy that does not require patient-specific manufacturing or ex vivo manipulation of patient samples. Having established the safety and individual immunologic activity of LV305 and G305 in prior studies, Immune Design initiated a new Phase 1B study of the product candidate CMB305 earlier this year.

About Soft Tissue Sarcoma

Soft Tissue Sarcomas (STS) are malignancies that arise from the soft tissues of the body, such as tissues that connect, support and surround other body structures including muscle, fat, blood vessels, nerves, tendons and the lining of joints.¹ In the United States, nearly 12,000 people will be diagnosed and approximately 4,870 are expected to die of STS in 2015.² There are approximately 50 different types of STS including Liposarcomas and Synovial Sarcomas, which are subtypes effecting fat tissue and tissue around the joints, respectively.³ Myxoid/round cell is a type of liposarcoma that accounts for approximately 30% of all liposarcoma cases.⁴ Myxoid and round cell liposarcoma and synovial sarcomas have been shown to have high expression of NY-ESO-1, approximately 90% and approximately 50%, respectively.⁵

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary focus of Immune Design’s ongoing immuno-oncology clinical programs, are products of its two synergistic discovery platforms, ZVex^TM and GLAAS^TM, the fundamental technologies of which were licensed from the California Institute of Technology and the Infectious Disease Research Institute (IDRI), respectively. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Immune Design’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing of initiation, progress, scope and outcome of clinical trials for Immune Design’s product candidates and the reporting of clinical data regarding Immune Design’s product candidates. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Immune Design’s collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Immune Design’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Immune Design’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Immune Design assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

¹ Mayo Clinic. Disease and Conditions: Soft tissue sarcoma.

Available at: http://www.mayoclinic.org/diseases-conditions/soft-tissue-sarcoma/basics/definition/con-20033386. Accessed: July 2015.

² National Cancer Institute. SEER Stat Fact Sheets: Soft Tissue including Heart Cancer.

Available at: http://seer.cancer.gov/statfacts/html/soft.html. Accessed: July 2015.

³ American Cancer Society. What is a soft tissue sarcoma?

Available at: http://www.cancer.org/cancer/sarcoma-adultsofttissuecancer/detailedguide/sarcoma-adult-soft-tissue-cancer-soft-tissue-sarcoma. Accessed: July 2015

⁴ Orpha.net. Myxoid/round cell liposarcoma.

Available at: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=99967. Accessed: July 2015.

⁵ Endo, M., et al. (April 2015). NY-ESO-1 (CTAG1B) expression in mesenchymal tumors [Abstract]. Modern Pathology, 28, 587-595.

Available at: http://www.nature.com/modpathol/journal/v28/n4/full/modpathol2014155a.html. Accessed: July 2015.

CONTACT: Media Contact
         Julie Rathbun
         Rathbun Communications
         julie@rathbuncomm.com
         206-769-9219

         Investor Contact
         Shari Annes
         Annes Associates
         sannes@annesassociates.com
         650-888-0902

(ECTE) Non-Invasive Continuous Glucose Monitoring System Likely Class 2 Medical Device in China

ISELIN, N.J., Aug. 12, 2015  — Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia (MTIA), Ltd., believes that Echo’s locally produced needle-free CGM products will be designated as a Class 2 medical device. Class 2 medical devices have a review period of 90 working days after filing submission with the Medical Device Evaluation Center of the China Food and Drug Administration (CFDA).  A formal and final designation from the CFDA is determined only at the time of submission.

As previously announced, Echo and MTIA are in the process of finalizing manufacturing assets in China and completing internal testing in support of the CFDA clinical trial and commercialization. Clinical sites for the approximately 120-patient trial have been identified and secured. Following CFDA approval, MTIA and Echo will share net sales of Echo’s CGM in the licensed territory.

“China represents the first key market for Echo and we are focused on supporting MTIA’s efforts to bring the technology to the 100 million diabetics in China. Additionally, we will build on this momentum as we move toward making our products accessible globally,” said Scott W. Hollander, Echo’s President and CEO. “In early June, I personally visited each of the manufacturing facilities in China and feel confident that MTIA has the assets in place to support their commercial efforts in the future.

“While the formal and final designation is never made until submission, my team and I continue to build a strong relationship with the CFDA while we work diligently to bring this important product to the market,” said Bai Ge, Managing Director of MTIA.

About Medical Technologies Innovation Asia

Medical Technologies Innovation Asia (MTIA) is a fully integrated medical device company focused on accelerating and delivering game-changing technologies that improve existing standards of care to meet unmet significant clinical needs and challenges, especially in oncology, diabetic, cardiovascular and other aging-related disease. Headquartered in Hong Kong, the company has manufacturing and sales facilities throughout mainland China. MTIA has established sales channels in more than 1,000 hospitals across China’s provinces, including national, top-tier regional and military institutions. MTIA is also the leading investor to pilot a number of State-Owned Enterprise giants of China in the healthcare area plus one of the potentially biggest market capitalization pharmaceutical companies who also has dramatic marketing and sales presence in the diabetic and cardiovascular disease treatment field.

About Echo Therapeutics

Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company’s CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the hospital settings. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo’s clinical studies, the safety and efficacy of Echo’s CGM System, the failure of future development and preliminary marketing efforts related to Echo’s CGM System, Echo’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo’s and its partners’ ability to develop, market and sell Echo’s CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its CGM System. These and other risks and uncertainties are identified and described in more detail in Echo’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2014, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(732) 549-0128

Connect With Us:
– Visit our website at www.echotx.com
– Follow us on Twitter at www.twitter.com/echotx
– Join us on Facebook at www.facebook.com/echotx

(EBIO) First Patients Dosed with EBI-005 in Phase 3 Allergic Conjunctivitis Study

Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced dose administration for the first patients in a Phase 3 study of EBI-005 for the treatment of moderate to severe allergic conjunctivitis. This Phase 3 study was designed and initiated following the completion in October 2014 of a Phase 2 study in which EBI-005 exhibited biological activity in improving the symptoms of late-phase allergic responses in patients with moderate to severe allergic conjunctivitis. This included statistically significant improvements in mean change from baseline in patient reported ocular itching, tearing and associated nasal symptoms compared to vehicle-control at the second to last and final assessment time points following allergen exposure in a modified direct conjunctival allergen provocation test (CAPT) model.

“Patient dosing in this Phase 3 study represents a significant step forward in the clinical development of EBI-005, a drug candidate with potential for the treatment of moderate to severe allergic conjunctivitis patients who are refractory to standard of care treatments for ocular allergy,” said Abbie Celniker, PhD, Chief Executive Officer of Eleven Biotherapeutics. “We look forward to reporting top line data from this Phase 3 study in the first quarter of 2016.”

“Many allergic conjunctivitis patients develop a late-phase severe allergic response which is not treated with antihistamines or mast cell stabilizers, the current standard of care. The ocular itching, tearing, redness and other symptoms, which if left untreated can become severe, resulting in chronic ocular pain, corneal scarring and distortion of vision. Currently, many of these patients are treated with topical steroids, which have a number of adverse side effects, including increased intraocular pressure and cataract formation,” said Dr. Victor Perez, Professor of Ophthalmology at Bascom Palmer Eye Institute. “EBI-005 offers the potential to mediate this late-phase allergic response by blocking the interleukin-1 (IL-1) receptor, believed to be responsible for the symptoms of ocular surface inflammation in diseases like allergic conjunctivitis, with an acceptable, long-term safety and tolerability profile.”

This multi-center, double-masked, randomized, vehicle controlled Phase 3 pivotal trial is designed to evaluate the safety and efficacy of EBI-005 for up to four weeks in patients with moderate to severe allergic conjunctivitis in an environmental setting. Approximately 250 patients will be randomized 1:1 to receive treatment with EBI-005 or with vehicle. If the results of this first Phase 3 trial are favorable, Eleven intends to initiate a second Phase 3 trial in the second half of 2016.

About EBI-005

Eleven Biotherapeutics’ most advanced product candidate is EBI-005, a novel, topically-administered interleukin-1 (IL-1) receptor blocker in development as a protein therapeutic for inflammatory diseases at the surface of the eye. The EBI-005 program is based on the role that elevated levels of the inflammatory cytokine IL-1 play in the initiation and maintenance of the inflammation, pain, redness, itching and other symptoms associated with ocular surface diseases. EBI-005 is currently in Phase 3 clinical development for the treatment of moderate to severe allergic conjunctivitis. In a completed Phase 2 clinical trial, EBI-005 exhibited biological activity in improving the symptoms of late-phase allergic responses in patients with moderate to severe allergic conjunctivitis in a (CAPT) model.

About Allergic Conjunctivitis

Allergic conjunctivitis (AC) affects the ocular surface and is characterized by symptoms of ocular itching, ocular tearing, ocular redness and associated nasal symptoms. If allergic conjunctivitis is left untreated or becomes severe, patients may suffer chronic ocular pain and distortion of vision that can significantly reduce their quality of life. Allergic conjunctivitis is a common cause of patient visits to eye care professionals in the United State. Allergic conjunctivitis affects 15% to 40% of the U.S. population. According to Eleven’s primary market research, in the United States 11 million patients seek medical treatment for allergic conjunctivitis annually. Of these patients, approximately 4 million have moderate allergic conjunctivitis and approximately 1.8 million have severe allergic conjunctivitis.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects. For more information please refer to the Company’s website www.elevenbio.com.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, advancement or maturation of its product candidates and product pipeline, clinical development of the Company’s therapeutic candidates, including expectations regarding timing of initiation of clinical trials, patient enrollment and availability of results, regulatory requirements for initiation of clinical trials and registration of product candidates, sufficiency of cash resources and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from ongoing clinical trials; whether results of early clinical trials will be indicative of the results of future trials; adequacy of any clinical models; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals and other factors discussed in the “Risk Factors” section of the Company’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on April 30, 2015 and other reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

(CERE) Awarded Patent for iCODE™ Trait Development System

– Company is deploying the innovative trait technology for corn, soybean, sorghum and other crops – Announcement follows recent patent award for an innovation in soybean related to plant processes that are the target of a class of commercial herbicides

THOUSAND OAKS, Calif., Aug. 12, 2015  — Ceres, Inc. (Nasdaq: CERE), an agricultural biotechnology company, has been awarded a U.S. patent for its iCODE multi-gene trait development system. The company indicated that the patent award is a key milestone in its plan to further develop and license this technology to other crop companies and organizations.

iCODE was developed to rapidly create, evaluate and select optimal combinations of genes and their control components for next-generation biotechnology traits in crops such as corn and soybean. The system is significantly more powerful than current practices. iCODE, which is an acronym for Intelligent Combinatorial Optimization and Directed Evolution, utilizes a plant cell’s own gene-shuffling system to create thousands of test plants with various novel combinations of pre-selected genes and promoters, which are the on-off switches for genes. Due to the efficiency of the system, Ceres says that iCODE can enable new kinds of discoveries and allow even smaller research programs to better compete against much larger competitors.

Ceres President and CEO Richard Hamilton noted that iCODE has the potential to revolutionize how traits are developed for many crops and can create new opportunities for intellectual property around proprietary combinations of genes and promoters. “Seed and trait companies rely on intellectual property protection, and iCODE could play a key role for companies attempting to access this new IP landscape. The first to unlock the potential will have a significant advantage in this area,” he suggested.

In practice, iCODE allows researchers to empirically test thousands of gene and promoter combinations in a single acre. Unlike first-generation traits, which usually consist of a single gene per trait, today’s biotech traits under development often pair multiple genes with multiple promoters to produce favorable characteristics. However, creating the thousands of combinations of genes and promoters that are required to identify the optimal candidates is time-consuming and costly, and has often eluded even the most robust trait development pipelines. iCODE helps solve this issue by providing an efficient, high-throughput approach.

The iCODE system is the latest in a line of innovations from Ceres. The company pioneered gene discovery and genome annotation through the use of high-throughput DNA sequencing systems in plants and was the first to utilize a two-species development system to identify plant genes that offer agronomic improvements— a system that was later followed by other plant science companies. Ceres is deploying the multi-gene trait development system internally and believes there are opportunities to out-license the system to other crop biotechnology companies. The company is currently in discussions with institutions and companies to establish best practices for evaluating the technology for larger scale deployment.

Today’s announcement follows a recent patent awarded to Ceres for a genetic sequence derived from soybean, covering uses of the gene in areas such as research, product development and plant transformation. The company believes that its gene is useful in regulating key biosynthetic processes that are the target of a class of commercial herbicides. Ceres plans to offer other seed companies a commercial license to the innovation, including an opportunity for exclusivity in certain crops.

The new patent announced today was issued by the U.S. Patent and Trademark Office as U.S. Patent No. 9,101,100 and is titled Methods and Materials for High Throughput Testing of Transgene Combinations. Ceres owns or maintains exclusive licensed rights to approximately 95 issued patents and numerous pending patent applications in the United States and in various foreign jurisdictions. A patent is an intellectual property right granted by a government to an inventor to exclude others from making, using, offering for sale, or selling the invention for a limited time in exchange for public disclosure of the invention when the patent is granted.

About Ceres
Ceres, Inc. is an agricultural biotechnology company that develops and markets seeds and traits to produce crops for animal feed, sugar and other markets. The company’s advanced plant breeding and biotechnology technology platforms, which can increase crop productivity, improve quality, reduce crop inputs and improve cultivation on marginal land, have broad application across multiple crops, including food, feed, fiber and fuel crops. Ceres markets its seed products under its Blade brand. The company also licenses its biotech traits and technology, including its Persephone genome visualization software, to other life science companies and organizations. iCODE is a trademark of Ceres.

Ceres Forward-Looking Statements
This press release may contain forward-looking statements. All statements, other than statements of historical facts, including statements regarding Ceres’ efforts to develop and commercialize its products and technologies, anticipated yields and product performance, status of crop plantings, short-term and long-term business strategies, market and industry expectations, future operating metrics, and future results of operations and financial position, including anticipated cost savings from the company’s restructuring plan and projected cash expenditures, are forward-looking statements. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Ceres’ control. Factors that could materially affect actual results can be found in Ceres’ filings with the U.S. Securities and Exchange Commission. Ceres undertakes no obligation to update publicly, except to the extent required by law, any forward-looking statements for any reason after the date the company issues this press release to conform these statements to actual results or to changes in the company’s expectations.

(AMRS) Biossance™ Brand Announces The Launch Of The Embodied Project

Beauty, Fitness, and Wellness Experts Candice Kumai, Vicky Vlachonis and Nitika Chopra will provide Tips and Information Throughout the Personal Journey to Self-betterment

EMERYVILLE, Calif., Aug. 11, 2015  — Today, Biossance™, the first consumer beauty brand from parent company Amyris, Inc. (NASDAQ: AMRS), is announcing their launch of The Embodied Project to support its first product Biossance™ The Revitalizer, a breakthrough facial moisturizer that replenishes the skin by using one of the emollients already found naturally within your body. The Embodied Project is a 30-day complimentary consultation program to encourage women to live life to the fullest and nurture their health in mind, body and spirit while elevating the beauty of their skin.

To take part in The Embodied Project, women are invited to take a two-minute survey to answer questions about their lifestyle and daily habits. Following the survey, each participant will receive a sample of The Revitalizer and will begin the four-week personal challenge consisting of curated content tailored just for them from beauty, wellness, and health experts Candice Kumai, Vicky Vlachonis and Nitika Chopra.  During this time, the experts will share daily tips, recipes, facts, and helpful content to guide the women as they work on becoming the best version of themselves.

The Revitalizer, which is the featured product in The Embodied Project, is a facial moisturizer made of 100% plant-derived squalane. Squalane is a natural moisturizer found within our skin that can diminish in some as early as their 20’s. The Revitalizer is a weightless moisturizer that instantly hydrates skin with a silky glow, is suitable for all skin types, and replenishes skin with what was once already there.

“I’m excited to be a part of the Biossance team and the rollout of the inspiring Embodied Project,” said Candice Kumai, wellness journalist, 5x bestselling author and chef. “As a chef and wellness journalist, it is essential to fuel your beautiful body with nutrients, and it’s just as important to be mindful of what you are putting on your body as well. The Revitalizer is the perfect beauty product for women to nurture their gorgeous bodies and glow from the inside-out!”

“Being a part of this program and having the opportunity to help women look and feel their best every day is a privilege and a passion of mine,” said Vicky Vlachonis, an osteopath and wellness expert. “It is so important to be mindful of yourself and your body, and with The Revitalizer, women can experience real results by restoring what already exists naturally in their bodies.”

“My love for inspirational beauty products fits in perfectly with the Biossance brand and it is exciting to watch the skincare line break through the beauty world,” said Nitika Chopra, certified life coach and wellness entrepreneur. “Sometimes all you need is a little push and motivation to truly feel empowered and that’s exactly what The Embodied Project is intended to do.”

The Revitalizer is currently offered in a 50ML bottle and available exclusively at Biossance.com. An expanded line of several other Biossance products will be available in 2016.

About Biossance
The Biossance brand, at its core, is dedicated to using science to make the scarce abundant, the rarified accessible, and the natural sustainable. The beauty of your skin relies on vital moisturizers found in your body, one of which is squalane. The Biossance brand’s patented, plant-derived emollient, Neossance® Squalane replenishes your skin by using a moisturizer found naturally in your body. This rich ingredient instantly hydrates while locking in essential moisture, leaving your skin feeling nourished and noticeably revitalized. The Biossance skincare line is designed with your own biological fingerprint in mind. We make what is already yours accessible again, turning the finite into the infinite. Sometimes all you need is a catalyst to nurture what’s within. Restore your own biological beauty.  More information about Biossance is available at www.Biossance.com.

About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.

Amyris, the Amyris logo, Neossance and Biossance are trademarks or registered trademarks of Amyris, Inc.

Media Contacts
Christine Coppinger
Sunshine Sachs
212.691.2800 | Amyris@sunshinesachs.com

Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
510.740.7481 | pr@amyris.com

(ABMD) Outlines Long-Term Growth Strategy, Unveils Future Products

DANVERS, Mass., Aug. 11, 2015  — Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, will present the Company’s long-term growth strategy and five- year vision for Impella® revenues during its annual investor conference today in Boston. The meeting will also include projected patient figures for the high-risk percutaneous coronary intervention (PCI) market, describe a new patient population of interest, and introduce future Impella products in the pipeline for heart failure, along with scientific and case presentations from leading physicians.

During the conference, Michael R. Minogue, Abiomed president, chairman and chief executive officer, and members of Abiomed’s management team will present the company’s long-range business plan with details on future product approvals, the size of relevant patient populations and the estimated Impella adoption rates for each patient group, and discuss marketing goals and objectives following the Protected PCI launch.

Among the specific topics to be presented at today’s event include:

• Treating Higher Risk Patients:  Leading physicians will present their experiences with Impella in both the surgical and catheterization lab settings, including a review of the recent TCTMD educational video on Protected PCI. Presentations will be given by: Mark Anderson, M.D., John Lasala, M.D., Jeffrey Moses, M.D., and George Vetrovec, M.D.
• Impella in the Post-PMA Era:  Management will present an in-depth look at the patient populations, market, and potential opportunity for Impella.  Some of those markets include:
  • Protected PCI patients – Abiomed estimates the urgent and elective high risk PCI patient population as a 121,000 annual patient opportunity.  With future PMA approvals, the emergent patient population remains at 100,000 patients.  During this presentation, Abiomed management will elaborate on several of the new marketing efforts used to drive elective and urgent Protected PCI utilization.
  • Chronic care patients — Abiomed is expanding its development focus to chronic care patients, centering on patient ambulation and mobilization, as well as new technologies. Abiomed continues to focus its efforts on native heart recovery and remodeling with intent to explant as a cost-effective strategy that promotes quality of life.
• Impella New Product Pipeline and Opportunity:  Management will review the pipeline and next-generation devices, including:
  • Impella Expandable Cardiac Power or “ECP”: The ECP pump is designed for blood flow of >3 liters/minute.  It is intended to be delivered on the standard Impella 9 Fr catheter and will include an 18 Fr expandable inflow in the left ventricle only with a smooth, clear, polyurethane membrane crossing the left ventricle.
  • Next Generation Impella CP:  The enhanced Impella CP pump is designed to have an increased flow of 4.5 liters/minute with improved inflow design and smart sensor technology.  It will be delivered on the standard Impella 9 Fr catheter and 14 Fr pump and is designed to provide support for up to 10 days.
  • Next Generation Impella 5.0: The “Impella 5.5”: The pump is designed for flow of 5.5 liters per minute.  It will be delivered on the standard 9 Fr catheter and includes a 19 Fr pump that is 45% shorter than the current Impella 5.0.  This pump is designed for duration of weeks to months.
  • Impella Bridge to Recovery or “BTR”: The Impella BTR is designed with similar specifications to the Impella 5.5 and is being developed with the intention of permitting patients to be discharged from the hospital with a wearable driver.  It is designed to provide support for months to years.
• The Five Year Vision for Growth and Financial Revenue Outlook: Management will review the potential opportunities for the new and existing Impella products and will also present a model of its vision for Impella revenues in the five-year time frame.  This model will reflect assumptions about the size of the accessible markets, average selling price (ASP) of Impella, and the financial impact of unlocking new patient opportunities.  These models indicate a potential of up to $1.2 to $1.8 billion in Impella revenues, and possibly larger with the receipt of future regulatory approvals for treatment of heart failure patients.  This revenue potential, in conjunction with operating leverage, will create a vision for a fast growing, 30%+ operating margin, business.

Members of the Abiomed management team scheduled to speak at today’s event include:

• Michael Minogue, Chief Executive Officer, President & Chairman
• Andrew Greenfield, Vice President & General Manager of Global Marketing
• Dr. Thorsten Siess, Chief Technology Officer
• Dr. David Weber, Chief Operating Officer

Abiomed invites its investors and potential investors to listen to the presentations via a live webcast that can be accessed under the Investor section of the company’s website at www.abiomed.com.  The presentations are scheduled to begin at approximately 9:00 a.m. EST. A replay of the webcast will be available on the Abiomed website for a brief period after the event.

ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com

FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed’s existing and new products, the Company’s progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

For further information please contact: 

Ingrid Goldberg
Director, Investor Relations
978-646-1590
ir@abiomed.com

(ABTL) to Present at the 35th Annual Canaccord Genuity Growth Conference

IRVINE, Calif., Aug. 11, 2015  — Autobytel Inc. (NASDAQ:ABTL), a leading provider of online automotive services dedicated to connecting consumers with dealers, has been invited to present at the 35^th Annual Canaccord Genuity Growth Conference being held August 12-13, 2015 at the InterContinental Boston Hotel.

Autobytel President and CEO Jeff Coats is scheduled to present on Thursday, August 13 at 2:30 p.m. Eastern time, with one-on-one meetings held throughout the day.

The presentation will be webcast live and available for replay at http://wsw.com/webcast/canaccord18/abtl and via the investor relations section of the company’s website at www.autobytel.com.

For more information about the conference or to schedule a one-on-one meeting with Autobytel management, please contact your Canaccord Genuity representative.

Tax Benefit Preservation Plan

At December 31, 2014, the company had approximately $94.5 million in available net operating loss carryforwards (“NOLs”) for U.S. federal income tax purposes.  The company’s Tax Benefit Preservation Plan (“Plan”) was adopted by the company’s Board of Directors to preserve the company’s NOLs and other tax attributes and thus reduce the risk of a possible change of ownership under Section 382 of the Internal Revenue Code.  Any such change of ownership under Section 382 would limit or eliminate the ability of the company to use its existing NOLs for federal income tax purposes.  Rights issued under the Plan could be triggered upon the acquisition by any person or group of 4.9% or more of the company’s outstanding common stock and could result in substantial dilution of the acquirer’s percentage ownership in the company.  As of August 4, 2015, there were 10,419,719 shares of the Company’s common stock outstanding. There is no guaranty that the Plan will achieve the objective of preserving the value of the company’s NOLs.  For more information, please visit http://investor.autobytel.com/tax.cfm.

About Autobytel Inc.

Autobytel Inc. provides high quality consumer leads and associated marketing services to automotive dealers and manufacturers throughout the United States.  The company also provides consumers with robust and original online automotive content to help them make informed car-buying decisions.  The company pioneered the automotive Internet in 1995 with its flagship website www.autobytel.com and has since helped tens of millions of automotive consumers research vehicles; connected thousands of dealers nationwide with motivated car buyers; and has helped every major automaker market its brand online.

Investors and other interested parties can receive Autobytel news alerts and special event invitations by accessing the online registration form at investor.autobytel.com/alerts.cfm.

CONTACT: Company Contact:
         Kim Boren
         Chief Financial Officer
         949-437-4694
         kimb@autobytel.com

         Investor Relations
         Liolios Group, Inc.
         Cody Slach or Sean Mansouri
         949-574-3860
         ABTL@liolios.com

(CLIR) Announces Installation and Operation of Duplex™ Technology at California Refinery

SEATTLE, Aug. 11, 2015  — ClearSign Combustion Corporation (NASDAQ: CLIR) announced today that it has successfully completed the initial installation of its Duplex™ technology in a multiple-burner, vertical-cylindrical production process heater at a California refinery. As previously announced, successful demonstration of Duplex at this facility will allow the refinery to meet strict environmental regulations for emissions of nitrogen oxides (NOx) and carbon monoxide (CO) in a cost-effective manner.

ClearSign and the customer are encouraged by the preliminary results achieved to date, which have shown a significant reduction in NOx emissions without the use of flue gas recirculation (FGR) or selective catalytic reduction (SCR). Additional testing leading to optimization of the technology will continue in order to reach the stated objectives of 6 ppm NOx, corrected to 3% O2.

The installation was completed within the customer’s allotted downtime period and was promptly returned to full production while testing continues.

About ClearSign Combustion Corporation

ClearSign Combustion Corporation designs, develops and markets technologies that drive to improve key performance characteristics of combustion systems, including emissions and operational performance, energy efficiency and overall cost-effectiveness. Our patent-pending Duplex™ and Electrodynamic Combustion Control™ platform technologies enhance the performance of combustion systems in a broad range of markets, including the chemical, petrochemical, refinery, power and commercial boiler industries. For more information, please visit www.clearsign.com

Cautionary note on forward-looking statements

This press release includes forward-looking information and statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for historical information contained in this release, statements in this release may constitute forward-looking statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events that are based on management’s belief, as well as assumptions made by, and information currently available to, management. While we believe that our expectations are based upon reasonable assumptions, there can be no assurances that our goals and strategy will be realized. Numerous factors may affect our actual results and may cause results to differ materially from those expressed in forward-looking statements made by us or on our behalf. Some of these factors include the acceptance of existing and future products, the impact of competitive products and pricing, general business and economic conditions, and other factors detailed in our Annual Report on Form 10-K and other periodic reports filed with the SEC. We specifically disclaim any obligation to update or revise any forward-looking statement whether as a result of new information, future developments or otherwise.

(CFRXW) Provides Update on CF-301 Phase 1 Trial

Study Continues as Planned for CF-301, Under Development for Staph Bloodstream Infections, Including MRSA

(NXTD) Issues Update; Major Progress Now On Sale

BOSTON, Aug. 11, 2015  — SoundView Technology Group (http://soundview.co) releases the following market and company update for NXT-ID, Inc. (NASDAQ: NXTD).

Market & Company Update

Summary

This season is famously bad in terms of liquidity in the stock market and especially for smaller, already thinly-traded issues. Since successfully launching their secure digital Wocket and raising capital to fund marketing and production expansion for the upcoming holiday season shares of NXTD have been cut in half since our last published update in June.

Part of the reason for the recent decline appears to be a direct result of a “sell” rating put on the shares by Zacks. It’s important to realize that the Zacks system is driven by a set of quantitative and backward-looking metrics. Their ratings are not based on what we would call traditional research into what future business trends will be. Methods like the one Zacks uses can be useful for well established companies like GE or Oracle but are worse than useless for emerging growth companies.

The situation is especially compelling given that NXT-ID remains precisely on the plan we dialed into to our estimates this year and next which feed directly into our Intrinsic Valuation (IV) value of $7.47/share. There are certainly some potential near-term events like distribution partnerships that we have not factored into our numbers as of yet.

What follows is a more detailed account of company progress in Q2, the plans and outlook for Q3 and Q4, the terms of the capital raise and adjustments to our IV model based on them.

Recent Results

The most significant accomplishment in Q2 was shipping the first batch of pre-orders. The company will recognize some revenue ($110K) for the quarter with the rest falling into Q3 due to the 2 week return period. Production level Wockets are in the field and being used. Initial indications are for an 80% success rate which is very good given the incredible diversity of POS devices and terminals. The company expects to get this up closer to 90% with some tweaks and software updates.

The second major hurdle cleared recently was obtaining the financing needed to fund the marketing and increased production required to be ready for the upcoming holiday shopping season. NXT-ID completed a $3 million equity capital raise that provides sufficient funding to ramp up production and marketing of the Wocket. The capital raise included 1,72 million shares of common stock at $1.75 per share as well a private placement of 860,716 warrants to purchase shares of common stock at an exercise price of $2.35 per share. If exercised NXT-ID would receive another $2M in funding,

Although nothing has been announced the management team has been working through a number of potential distribution arrangements and becoming operationally ready to be able to run at a 10,000 unit per month delivery rate.

One stealthy but potentially important note on recent results was the filing for a patent covering “Crypto-Currency Management” which isn’t a near-term driver but as the momentum behind blockchain-based technology keeps expanding the ability to address non-traditional digital currency will be important. (see further blockchain-related comments in the market section below.)

Market Update

The digital payments space has remained a hotbed of activity with PayPal now a separate public company (NASDAQ:PYPL) and Visa (NYSE:V) teaming up and funding Stripe. The proliferation of devices that can tie into future payment systems (like the Apple Watch and Moto 360) helps justify infrastructure updates that will make payments easier across a broad array of types – from cards to Wockets to phones to watches.

EMV has been in the news and NXT-ID has been planning for it for a long time. In order to fully support EMV the Wocket will be upgraded to include EMV and NFC technologies. It will take EMV quite some to roll out to the masses of terminals out there so an upgraded Wocket later this year will enable consumers to use these terminals when they begin to encounter them.

We’ve seen an explosion of activity around generalizing the blockchain technology underlying Bitcoin for all sorts of transactional applications. It may help legitimize usage. Although the Wocket isn’t about Bitcoin per se it’s in a good position to help consumers who want to use Bitcoin or other digital currencies.

Anecdotally we noted more “Bitcoin accepted here” signs on Cape Cod this summer. We made some inquiries and although usage is not commonplace in general more travelers are using Bitcoin as a kind of standard currency when they can. Rather than convert Euros to dollars they have brought Bitcoin. Maybe this is just due to the recent weakness in the Euro, or maybe it’s a trend. In any case this is the first time we’ve come into contact with Bitcoin run-of-the-mill consumer locations like restaurants, amusement parks and gift shops.

The events and players are distinct but in general the market is “more of the same” which is a concerted movement toward more digital, more secure and more mobile payments which is exactly where the Wocket fits. It remains to be seen how consumers sift through the myriad offerings and settle into what works for them. As we’ve stated before the Wocket is unique as an actual wallet replacement rather than something that is an extension of your smartphone.

Stock Conclusion

In the few years we’ve been working with and following NXT-ID the current moment offers the best risk/reward we’ve seen so far. The company has come a very long way since their IPO at $1 and seen share prices as high as $5.60 with a substantial period trading between $4-5/share.

There are a few reasons we can point to in the short term – limited liquidity, a spurious and backward-looking downgrade from Zacks in the headlines and general “risk off” mentality as the world grapples with slowing growth and rising (at least in the US) interest rates.

We remain comfortable with our 40,000 unit assumption for 2015 based on the planned marketing campaign in Q3, a monthly production goal of 10,000 units and the upcoming holiday buying season. Market data suggests there is already demand for 100,000 to 200,000 units if it can be reached and serviced so at this point demand isn’t a limiting factor. Looking further out into 2016 our 120,000 unit number isn’t aggressive either.

We’re tweaking our model to account for some more shares outstanding and also took the opportunity to add expenses for SG&A to support increased marketing and operational readiness. It has had only a minor impact on the IV estimate – taking it from $8.28 to $7.47.

As we mentioned at the start of the note the risk/return from the current stock level is very attractive. Longer-term investors will also note that our the IV for 2016 doubles so if NXT-ID exits 2015 with good momentum there is quite a bit of additional upside

The NXT research update (PDF) is also published and available here:

http://s3.amazonaws.com/Published_Research/NXT-ID_NXTD_SV_NOTE_AUGUST_2015.pdf

Past reports and related research can be found on our website at http://soundview.co/infosec.

Editor’s Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

Glossary of Terms

IV or Intrinsic Value is our method of evaluating growth stocks. Over the last twenty years we’ve found that most traditional measures like P/E, PEG, and even DCF models are not effective at arriving at a single price point that represents the true value of the future prospects of a company. It has some things in common with a DCF approach but deviates by focusing instead on long-term market value since it’s more akin to what a growth stock delivers than stable cash flows.

POS is an abbreviation for “Point of Sale” systems which include terminals which handle your credit cards to back office computers that interface with the large payment processors and gateways.

Disclosures

SoundView serves as a strategic advisor to NXT-ID and provides this research note for informational purposes only. SoundView does not have “ratings” and is not an investment bank, broker/dealer or registered investment advisor. We’ve undertaken to research all facts presented here but can make no promises that they are correct or that our reasoning and supporting intrinsic valuation model is an accurate depiction of the future. SoundView employees may have positions in stocks they work on however at the time of this writing we are not aware of any outstanding positions in the shares of NXT-ID.

About NXT- ID Inc. – Mobile Security for a Mobile World: (NXTD) (NXTDW):

NXT-ID, Inc.’s innovative MobileBio® solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio® suite of biometric solutions that secure consumers’ mobile platforms led by Wocket® ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. Wocket was recognized as one of the top technology products at CES 2015 by multiple media outlets including Wired.com. The Wocket works most anywhere credit cards are accepted and only works with your biometric stamp of approval or passcode.

http://www.wocketwallet.com/

NXT-ID’s wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification and has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/

Contact:
Kris Tuttle
SoundView Technology Group
kris@soundview.co
+1-617-828-6462